Frequency Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
April 09 2021 - 6:00AM
Business Wire
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage
biotechnology company focused on harnessing the body’s innate
biology to repair or reverse damage caused by a broad range of
degenerative diseases, today announced that Chief Executive Officer
David L. Lucchino will present a company overview at the 20th
Annual Needham Virtual Healthcare Conference.
Mr. Lucchino’s presentation will take place on Wednesday, April
14 at 8:00 a.m. EDT.
A live webcast of the presentation can be accessed on the
investors section of Frequency’s website,
investors.frequencytx.com. A replay of the presentation will be
posted on the Frequency website following the event.
About Frequency Therapeutics
Frequency Therapeutics is a leader in the development of
medicines designed to activate progenitor cells within the body to
treat degenerative diseases. The Company’s progenitor cell
activation (PCA) approach stimulates progenitor cells to create
functional tissue with the aim of developing disease modifying
therapies. The Company’s lead product candidate, FX-322, is
designed to regenerate auditory hair cells to restore hearing
function. FX-322 is being evaluated in multiple ongoing clinical
studies in patients with sensorineural hearing loss. The Company
also is evaluating additional diseases where its PCA approach could
create functional tissue, including in a pre-clinical program in
multiple sclerosis.
Headquartered in Woburn, Mass., Frequency has an ex-U.S. license
and collaboration agreement with Astellas Pharma Inc. for FX-322,
as well as additional collaboration and licensing agreements with
academic and nonprofit research organizations including
Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts
Institute of Technology, The Scripps Research Institute and
Cambridge Enterprises Limited. For more information, visit
www.frequencytx.com and follow Frequency on Twitter
@Frequencytx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210409005033/en/
Investor Contact: Carlo Tanzi, Ph.D. Kendall Investor Relations
ctanzi@kendallir.com 617-914-0008
Media Contact: Suzanne Day Frequency Therapeutics
sday@frequencytx.com 781-496-2211
Frequency Therapeutics (NASDAQ:FREQ)
Historical Stock Chart
From Apr 2024 to May 2024
Frequency Therapeutics (NASDAQ:FREQ)
Historical Stock Chart
From May 2023 to May 2024